title: Fenoldopam use in a burn intensive care unit: a retrospective study.
abstract: BACKGROUND
  Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our study was to describe our use of low-dose fenoldopam (0.03-0.09 mug/kg/min) infusion in critically ill burn patients with AKI.
  
  
  METHODS
  We performed a retrospective analysis of consecutive patients admitted to our burn intensive care unit (BICU) with severe burns from November 2005 through September 2008 who received low-dose fenoldopam. Data obtained included systolic blood pressure, serum creatinine, vasoactive medication use, urine output, and intravenous fluid. Patients on concomitant continuous renal replacement therapy were excluded. Modified inotrope score and vasopressor dependency index were calculated. One-way analysis of variance with repeated measures, Wilcoxson signed rank, and chi-square tests were used. Differences were deemed significant at p < 0.05.
  
  
  RESULTS
  Seventy-seven patients were treated with low-dose fenoldopam out of 758 BICU admissions (10%). Twenty (26%) were AKI network (AKIN) stage 1, 14 (18%) were AKIN stage 2, 42 (55%) were AKIN stage 3, and 1 (1%) was AKIN stage 0. Serum creatinine improved over the first 24 hours and continued to improve through 48 hours (p < 0.05). There was an increase in systolic blood pressure in the first 24 hours that was sustained through 48 hours after initiation of fenoldopam (p < 0.05). Urine output increased after initiation of fenoldopam without an increase in intravenous fluid requirement (p < 0.05; p = NS). Modified inotrope score and vasopressor dependency index both decreased over 48 hours (p < 0.0001; p = 0.0012).
  
  
  CONCLUSIONS
  These findings suggest that renal function was preserved and that urine output improved without a decrease in systolic blood pressure, increase in vasoactive medication use, or an increase in resuscitation requirement in patients treated with low-dose fenoldopam. A randomized controlled trial is required to establish the efficacy of low-dose fenoldopam in critically ill burn patients with AKI.
authors.affiliation: United States Army Institute of Surgical Research, 3400 Rawley E, Chambers Avenue, Fort Sam Houston, Texas, 78234, USA . john.simmons@amedd.army.mil.
authors.forename: John W
authors.initials: JW
authors.lastname: Simmons
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Chung
authors.forename: Evan M
authors.initials: EM
authors.lastname: Renz
authors.forename: Christopher E
authors.initials: CE
authors.lastname: White
authors.forename: Casey L
authors.initials: CL
authors.lastname: Cotant
authors.forename: Molly A
authors.initials: MA
authors.lastname: Tilley
authors.forename: Mark O
authors.initials: MO
authors.lastname: Hardin
authors.forename: John A
authors.initials: JA
authors.lastname: Jones
authors.forename: Lorne H
authors.initials: LH
authors.lastname: Blackbourne
authors.forename: Steven E
authors.initials: SE
authors.lastname: Wolf